Data presented at 75th American Diabetes Association Scientific Sessions® bolster existing information on Trulicity's safety and efficacy
New Data Show Superiority of Lilly's Once-Weekly Trulicity™ (dulaglutide) to Lantus® (insulin glargine) in Patients with Type 2 Diabetes (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.